Literature DB >> 11560194

Differential transcription factor expression in human mononuclear cells in response to amphotericin B: identification with complementary DNA microarray technology.

J D Cleary1, P D Rogers, S W Chapman.   

Abstract

STUDY
OBJECTIVE: To identify genes differentially expressed in human monocytic cells exposed to amphotericin B in vitro.
DESIGN: In vitro experiment.
SETTING: Hospital laboratory. MATERIAL: Human mononuclear cell line, THP-1. INTERVENTION: Human mononuclear cells were exposed to amphotericin B or media alone for 6 hours. After exposure, total RNA was isolated and reverse transcribed to complementary DNA. Differences in probe hybridization observed during blotting were measured, and genes with altered regulation were described by using human complementary DNA microarray technology.
MEASUREMENTS AND MAIN RESULTS: Of 588 genes represented on the array, 16 transcripts were found to be upregulated and 4 transcripts were downregulated in response to amphotericin B. These findings suggest that amphotericin B alters the expression of genes in human monocytic cells that play a role in many cellular functions, including immune response, signal transduction, and cell differentiation.
CONCLUSION: Amphotericin B induces alterations in human cell gene transcription. These changes could be used to evaluate differences in toxicity or efficacy observed in patients receiving this agent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560194     DOI: 10.1592/phco.21.13.1046.34619

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  2 in total

1.  Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.

Authors:  Lloyd W Turtinen; David N Prall; Lindsay A Bremer; Rachel E Nauss; Scott C Hartsel
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 2.  Guided tissue regeneration in heart valve replacement: from preclinical research to first-in-human trials.

Authors:  L Iop; G Gerosa
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.